UK Surgical Sealant Film developer Tissuemed Ltd has appointed Dr David Mandley as its new CEO, succeeding interim CEO Jeremy Sampson in the role. Dr Mandley has worked for over ten years in the company and has been a director for four of those years. Prior to his appointment as CEO Dr Mandley had responsibility for Tissuemed’s Regulatory and Quality functions and has also been a driving force behind the company’s efforts to develop strong relationships with surgeons across Europe and USA who have been using or evaluating the existing products, collaborating on clinical studies or developing new sealant film iterations. He has also developed strong relationships with Tissuemed’s growing international distributor network.
At the same time as announcing Dr Mandley’s appointment the company has also appointed a new Non Executive Director in the form of Gordon Sutherland. Mr Sutherland has worked in the healthcare industry for over 30 years having held senior positions with Johnson and Johnson, Convatec-Bristol Myers Squibb and Baxter Biosurgery Europe prior to his current role with Gambro.
Source: Tissuemed Ltd